Q2-osavuosiraportti
Vain PDF
27 päivää sitten
Tarjoustasot
First North Sweden
Määrä
Osto
596
Myynti
Määrä
2 954
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 114 | - | - | ||
| 157 | - | - | ||
| 10 | - | - | ||
| 152 | - | - | ||
| 50 | - | - |
Ylin
9,02VWAP
Alin
8,11VaihtoMäärä
1,5 172 831
VWAP
Ylin
9,02Alin
8,11VaihtoMäärä
1,5 172 831
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 174 331 | 174 331 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 174 331 | 174 331 | 0 | 0 |
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q3-osavuosiraportti | 14.11. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q2-osavuosiraportti | 22.8. | |
| 2024 Yhtiökokous | 27.6. | |
| 2025 Q1-osavuosiraportti | 16.5. | |
| 2024 Q4-osavuosiraportti | 21.2. | |
| 2024 Q3-osavuosiraportti | 31.10.2024 |
Datan lähde: Millistream, Quartr
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
9.9.9.9.Innebörden av FDA godkännandet för 1.5T som meddelades i förra veckan: The company said that this expanded labeling could significantly increase the system’s market opportunity within the US, where 1.5T MRI systems account for approximately 60 percent of clinical use. With 1.5T systems estimated to represent over 70 percent of the global installed MRI base, this clearance positions ClearPoint Prism for significant growth internationally as well. "The expanded labeling for ClearPoint Prism is perfect timing for the company as it delivers added fuel to our 2025 growth initiatives, which we call Fast Forward," commented Joe Burnett, President & CEO at ClearPoint Neuro. He continued, "This product will contribute meaningfully to these goals, both today and tomorrow. In the immediate term, we are excited to bring the benefits of ClearPoint Prism to hospitals that did not have the previously cleared MRI scanner available. As a reminder, our Functional Neurosurgery disposable products, including ClearPoint Prism laser applicators, grew 70 percent in the first quarter and 33 percent in the second quarter of this year. That growth was accomplished with one hand tied behind our back as we had access to less than 50 percent of the neuro LITT market. That hand is no longer tied. The longer-term benefits are more subtle but equally important.” Chris Osswald, Director and Global Segment Leader for Laser Therapy, added that they plan to enter full market release on 1.5T immediately.- 5.9.·For those who don't know the case. CLS sells laser systems to its partner Clearpoint neuro in the USA. They have exclusive rights to the CLS system worldwide in neuro. CLPT has raised a hell of a lot of capital to escalate the introduction of the joint system Prism to its existing customers, as well as new ones. Among other things, by providing systems at no upfront cost to the hospital. CLS still gets paid upon delivery, however, CLPT takes the cost of this. For each treatment, (brain tumors, epilepsy, Parkinson's on the rise) a number of laser fibers and some other equipment are used, this gives approx. 45Ksek in revenue per treatment to CLS. CLS has a ~80% margin on this. Right now, approx. 1 1/2 years after the first systems came out on the commercial market, there are approx. 30 systems out there. These generated ~6-7 MSEK in revenue during Q2 this year. Calculate 30 systems that treat 30 patients per year at 45Ksek and 80% margin and we get 32Msek in profit from consumables per year, only on existing installations as potential income when the hospitals are up and running and treating. Consider that today's FDA approval opens up the remaining half of the market in neuro, which uses 1.5 Tesla. And that the market for LiTT is maturing rapidly right now in most indications, and you can see how big this will be. In the long term, urology/prostate will be added, where the side effect profile is very good and the procedures can be done at local clinics with a return home within an hour. Best of all, the company's valuation has barely begun yet. The history of new issues has been haunted, which gives this unique opportunity to step on a future multi-billion dollar company at a valuation of a paltry ~400Msek, with secured finances and started sales, where you are close to breaking even.
1.9.·What is behind the rise in G? Should they be approved by the FDA?2.9. · Muokattu·FDA is more or less priced in, everyone knows that it is only a matter of time. The rise is driven by the fact that the company has been extremely depressed, close to bankruptcy valuation, due to several bad new issues with high dilution and erosion of the share value as a result. In combination with high costs, poor sales, the market was skeptical of the company's forecast of reaching profitability in the foreseeable future. Now they have got a capable board in place, landed a good directed issue to long-term investors and secured capital for BE. They have shown that the forecast is correct, both when it comes to the reduced costs but also that the announced revenue increase now feels feasible. The company is therefore a completely different company compared to just 6 months ago.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Q2-osavuosiraportti
Vain PDF
27 päivää sitten
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- 9.9.9.9.Innebörden av FDA godkännandet för 1.5T som meddelades i förra veckan: The company said that this expanded labeling could significantly increase the system’s market opportunity within the US, where 1.5T MRI systems account for approximately 60 percent of clinical use. With 1.5T systems estimated to represent over 70 percent of the global installed MRI base, this clearance positions ClearPoint Prism for significant growth internationally as well. "The expanded labeling for ClearPoint Prism is perfect timing for the company as it delivers added fuel to our 2025 growth initiatives, which we call Fast Forward," commented Joe Burnett, President & CEO at ClearPoint Neuro. He continued, "This product will contribute meaningfully to these goals, both today and tomorrow. In the immediate term, we are excited to bring the benefits of ClearPoint Prism to hospitals that did not have the previously cleared MRI scanner available. As a reminder, our Functional Neurosurgery disposable products, including ClearPoint Prism laser applicators, grew 70 percent in the first quarter and 33 percent in the second quarter of this year. That growth was accomplished with one hand tied behind our back as we had access to less than 50 percent of the neuro LITT market. That hand is no longer tied. The longer-term benefits are more subtle but equally important.” Chris Osswald, Director and Global Segment Leader for Laser Therapy, added that they plan to enter full market release on 1.5T immediately.
- 5.9.·For those who don't know the case. CLS sells laser systems to its partner Clearpoint neuro in the USA. They have exclusive rights to the CLS system worldwide in neuro. CLPT has raised a hell of a lot of capital to escalate the introduction of the joint system Prism to its existing customers, as well as new ones. Among other things, by providing systems at no upfront cost to the hospital. CLS still gets paid upon delivery, however, CLPT takes the cost of this. For each treatment, (brain tumors, epilepsy, Parkinson's on the rise) a number of laser fibers and some other equipment are used, this gives approx. 45Ksek in revenue per treatment to CLS. CLS has a ~80% margin on this. Right now, approx. 1 1/2 years after the first systems came out on the commercial market, there are approx. 30 systems out there. These generated ~6-7 MSEK in revenue during Q2 this year. Calculate 30 systems that treat 30 patients per year at 45Ksek and 80% margin and we get 32Msek in profit from consumables per year, only on existing installations as potential income when the hospitals are up and running and treating. Consider that today's FDA approval opens up the remaining half of the market in neuro, which uses 1.5 Tesla. And that the market for LiTT is maturing rapidly right now in most indications, and you can see how big this will be. In the long term, urology/prostate will be added, where the side effect profile is very good and the procedures can be done at local clinics with a return home within an hour. Best of all, the company's valuation has barely begun yet. The history of new issues has been haunted, which gives this unique opportunity to step on a future multi-billion dollar company at a valuation of a paltry ~400Msek, with secured finances and started sales, where you are close to breaking even.
- 1.9.·What is behind the rise in G? Should they be approved by the FDA?2.9. · Muokattu·FDA is more or less priced in, everyone knows that it is only a matter of time. The rise is driven by the fact that the company has been extremely depressed, close to bankruptcy valuation, due to several bad new issues with high dilution and erosion of the share value as a result. In combination with high costs, poor sales, the market was skeptical of the company's forecast of reaching profitability in the foreseeable future. Now they have got a capable board in place, landed a good directed issue to long-term investors and secured capital for BE. They have shown that the forecast is correct, both when it comes to the reduced costs but also that the announced revenue increase now feels feasible. The company is therefore a completely different company compared to just 6 months ago.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
First North Sweden
Määrä
Osto
596
Myynti
Määrä
2 954
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 114 | - | - | ||
| 157 | - | - | ||
| 10 | - | - | ||
| 152 | - | - | ||
| 50 | - | - |
Ylin
9,02VWAP
Alin
8,11VaihtoMäärä
1,5 172 831
VWAP
Ylin
9,02Alin
8,11VaihtoMäärä
1,5 172 831
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 174 331 | 174 331 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 174 331 | 174 331 | 0 | 0 |
Asiakkaat katsoivat myös
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q3-osavuosiraportti | 14.11. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q2-osavuosiraportti | 22.8. | |
| 2024 Yhtiökokous | 27.6. | |
| 2025 Q1-osavuosiraportti | 16.5. | |
| 2024 Q4-osavuosiraportti | 21.2. | |
| 2024 Q3-osavuosiraportti | 31.10.2024 |
Datan lähde: Millistream, Quartr
Q2-osavuosiraportti
Vain PDF
27 päivää sitten
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q3-osavuosiraportti | 14.11. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q2-osavuosiraportti | 22.8. | |
| 2024 Yhtiökokous | 27.6. | |
| 2025 Q1-osavuosiraportti | 16.5. | |
| 2024 Q4-osavuosiraportti | 21.2. | |
| 2024 Q3-osavuosiraportti | 31.10.2024 |
Datan lähde: Millistream, Quartr
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- 9.9.9.9.Innebörden av FDA godkännandet för 1.5T som meddelades i förra veckan: The company said that this expanded labeling could significantly increase the system’s market opportunity within the US, where 1.5T MRI systems account for approximately 60 percent of clinical use. With 1.5T systems estimated to represent over 70 percent of the global installed MRI base, this clearance positions ClearPoint Prism for significant growth internationally as well. "The expanded labeling for ClearPoint Prism is perfect timing for the company as it delivers added fuel to our 2025 growth initiatives, which we call Fast Forward," commented Joe Burnett, President & CEO at ClearPoint Neuro. He continued, "This product will contribute meaningfully to these goals, both today and tomorrow. In the immediate term, we are excited to bring the benefits of ClearPoint Prism to hospitals that did not have the previously cleared MRI scanner available. As a reminder, our Functional Neurosurgery disposable products, including ClearPoint Prism laser applicators, grew 70 percent in the first quarter and 33 percent in the second quarter of this year. That growth was accomplished with one hand tied behind our back as we had access to less than 50 percent of the neuro LITT market. That hand is no longer tied. The longer-term benefits are more subtle but equally important.” Chris Osswald, Director and Global Segment Leader for Laser Therapy, added that they plan to enter full market release on 1.5T immediately.
- 5.9.·For those who don't know the case. CLS sells laser systems to its partner Clearpoint neuro in the USA. They have exclusive rights to the CLS system worldwide in neuro. CLPT has raised a hell of a lot of capital to escalate the introduction of the joint system Prism to its existing customers, as well as new ones. Among other things, by providing systems at no upfront cost to the hospital. CLS still gets paid upon delivery, however, CLPT takes the cost of this. For each treatment, (brain tumors, epilepsy, Parkinson's on the rise) a number of laser fibers and some other equipment are used, this gives approx. 45Ksek in revenue per treatment to CLS. CLS has a ~80% margin on this. Right now, approx. 1 1/2 years after the first systems came out on the commercial market, there are approx. 30 systems out there. These generated ~6-7 MSEK in revenue during Q2 this year. Calculate 30 systems that treat 30 patients per year at 45Ksek and 80% margin and we get 32Msek in profit from consumables per year, only on existing installations as potential income when the hospitals are up and running and treating. Consider that today's FDA approval opens up the remaining half of the market in neuro, which uses 1.5 Tesla. And that the market for LiTT is maturing rapidly right now in most indications, and you can see how big this will be. In the long term, urology/prostate will be added, where the side effect profile is very good and the procedures can be done at local clinics with a return home within an hour. Best of all, the company's valuation has barely begun yet. The history of new issues has been haunted, which gives this unique opportunity to step on a future multi-billion dollar company at a valuation of a paltry ~400Msek, with secured finances and started sales, where you are close to breaking even.
- 1.9.·What is behind the rise in G? Should they be approved by the FDA?2.9. · Muokattu·FDA is more or less priced in, everyone knows that it is only a matter of time. The rise is driven by the fact that the company has been extremely depressed, close to bankruptcy valuation, due to several bad new issues with high dilution and erosion of the share value as a result. In combination with high costs, poor sales, the market was skeptical of the company's forecast of reaching profitability in the foreseeable future. Now they have got a capable board in place, landed a good directed issue to long-term investors and secured capital for BE. They have shown that the forecast is correct, both when it comes to the reduced costs but also that the announced revenue increase now feels feasible. The company is therefore a completely different company compared to just 6 months ago.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
First North Sweden
Määrä
Osto
596
Myynti
Määrä
2 954
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 114 | - | - | ||
| 157 | - | - | ||
| 10 | - | - | ||
| 152 | - | - | ||
| 50 | - | - |
Ylin
9,02VWAP
Alin
8,11VaihtoMäärä
1,5 172 831
VWAP
Ylin
9,02Alin
8,11VaihtoMäärä
1,5 172 831
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 174 331 | 174 331 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 174 331 | 174 331 | 0 | 0 |